SCHEMBL3140634

SCHEMBL3140634

O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cccnc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.67
KMT2A Q03164 5/20 0.64
MEN1 O00255 4/20 0.64
NPC1 O15118 2/20 0.63
P2RX1 P51575 1/20 0.61
PTGS1 P23219 1/20 0.60
CASP3 P42574 1/20 0.60
RAB9A P51151 1/20 0.60
SENP8 Q96LD8 1/20 0.60
SENP7 Q9BQF6 1/20 0.60
SENP6 Q9GZR1 1/20 0.60
RXFP1 Q9HBX9 7/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 2/20 0.59
HTT P42858 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
HPGD P15428 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
EGLN1 Q9GZT9 1/20 0.59
KDM4E B2RXH2 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7686886 0.88 EGLN1 (0.77) MAPTKMT2AMEN1P2RX1RXFP1
SCHEMBL3043442 0.87 EGLN1 (0.76) MAPTKMT2AMEN1NPC1PTGS1
SCHEMBL23847684 0.85 P2RX1 (0.67) MAPTKMT2AMEN1P2RX1PTGS1
SCHEMBL3113627 0.84 PTGS1 (0.68) MAPTKMT2AMEN1P2RX1PTGS1
SCHEMBL3110003 0.84 KMT2A (0.65) MAPTKMT2AMEN1P2RX1PTGS1
SCHEMBL3041133 0.81 NPC1 (0.76) MAPTKMT2AMEN1NPC1CASP3
SCHEMBL27652617 0.79 RXFP1 (0.88) MAPTP2RX1PTGS1RXFP1
SCHEMBL30674279 0.79 FGFR4 (0.71) KMT2AMEN1NPC1PTGS1CASP3
SCHEMBL24172760 0.79 FGFR4 (0.71) KMT2AMEN1NPC1PTGS1CASP3
SCHEMBL8311076 0.78 EGLN1 (0.80) MAPTP2RX1ALDH1A1EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100247622-A1 TREATMENT REGIME FOR PROLIFERATIVE DISORDERS ONCOLYTICS BIOTECH INC. (CA) 2010-09-30 US disclosed
CN-101820892-A Treatment regime for proliferative disorders ONCOLYTICS BIOTECH INC 2010-09-01 CN disclosed
WO-2009052617-A9 TREATMENT REGIME FOR PROLIFERATIVE DISORDERS ONCOLYTICS BIOTECH INC. (CA) 2010-08-05 WO disclosed
EP-2211880-A1 TREATMENT REGIME FOR PROLIFERATIVE DISORDERS Oncolytics Biotech Inc. (CA) 2010-08-04 EP disclosed
WO-2009052617-A1 TREATMENT REGIME FOR PROLIFERATIVE DISORDERS ONCOLYTICS BIOTECH INC. (CA) 2009-04-30 WO disclosed